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OBJECTIVE—To determine whether the obesity-related decre-
ment in fatty acid oxidation (FAO) in primary human skeletal
muscle cells (HSkMC) is linked with lower mitochondrial content
and whether this deﬁcit could be corrected via overexpression
of peroxisome proliferator–activated receptor- coactivator-1
(PGC-1).
RESEARCH DESIGN AND METHODS—FAO was studied in
HSkMC from lean (BMI 22.4  0.9 kg/m
2; N  12) and extremely
obese (45.3  1.4 kg/m
2; N  9) subjects. Recombinant adeno-
virus was used to increase HSkMC PGC-1 expression (3.5- and
8.0-fold), followed by assessment of mitochondrial content (mtDNA
and cytochrome C oxidase IV [COXIV]), complete (
14CO2 produc-
tion from labeled oleate), and incomplete (acid soluble metabolites
[ASM]) FAO, and glycerolipid synthesis.
RESULTS—Obesity was associated with a 30% decrease (P 
0.05) in complete FAO, which was accompanied by higher
relative rates of incomplete FAO ([
14C]ASM production/
14CO2),
increased partitioning of fatty acid toward storage, and lower
(P  0.05) mtDNA (27%), COXIV (35%), and mitochondrial
transcription factor (mtTFA) (43%) protein levels. PGC-1
overexpression increased (P  0.05) FAO, mtDNA, COXIV,
mtTFA, and fatty acid incorporation into triacylglycerol in both
lean and obese groups. Perturbations in FAO, triacylglycerol
synthesis, mtDNA, COXIV, and mtTFA in obese compared with
lean HSkMC persisted despite PGC-1 overexpression. When
adjusted for mtDNA and COXIV content, FAO was equivalent
between lean and obese groups.
CONCLUSION—Reduced mitochondrial content is related to
impaired FAO in HSkMC derived from obese individuals. Increas-
ing PGC-1 protein levels did not correct the obesity-related
absolute reduction in FAO or mtDNA content, implicating mech-
anisms other than PGC-1 abundance. Diabetes 59:1407–1415,
2010
T
he skeletal muscle of obese individuals typically
exhibits an inability to effectively oxidize lipid.
Using arteriovenous difference measurements
across a skeletal muscle bed, Kelly et al. (1)
observed a signiﬁcant reduction of in vivo fatty acid
oxidation (FAO) in obese versus lean subjects. Our labo-
ratory has reported a consistent reduction in FAO in
skeletal muscle from individuals with extreme or class III
(BMI 40 kg/m
2) obesity in a variety of preparations such
as muscle homogenates from the vastus lateralis (2), intact
muscle strips from the rectus abdominus (3), and in vivo
when examining substrate utilization (indirect calorime-
try) during exercise (4) or when determining the fate of
infused lipid (5). While the speciﬁc mechanism(s) respon-
sible for the impairment remains unknown, it has been
hypothesized that decreased mitochondrial content (6) or
function (7) contributes to this obesity-related phenotype.
A reduction in skeletal muscle mitochondrial DNA (mtDNA)
(7), altered mitochondria morphology (8), and decrements
in mitochondrial enzyme activity (2,9) have all been asso-
ciated with obesity/diabetes and may contribute to the
decreased capacity for FAO.
The depression of FAO in skeletal muscle with obesity is
of concern as this defect may contribute to lipid accumu-
lation within the myocyte and the onset of insulin resis-
tance (3,10–12); a reduced capacity for lipid oxidation is
also associated with weight gain (2). In terms of interven-
tion, weight loss does not appear to reverse the obesity-
associated reduction in skeletal muscle FAO (5,13). In
contrast, we recently reported that only 10 days of exer-
cise training (60 min/day) increased FAO in the skeletal
muscle of previously extremely obese subjects; a novel
ﬁnding was that physical activity overcame the initial
decrement in FAO with obesity and elevated FAO to an
equivalent absolute value in both lean and obese individ-
uals (13). These data suggest that contractile activity,
through a yet undeﬁned mechanism is an effective inter-
vention for the decrement in FAO reported with obesity.
Peroxisome proliferator–activated receptor- coactiva-
tor-1 (PGC-1) is a metabolic coactivator that binds to
transcription factors stimulating mitochondrial biogenesis
(14) and lipid oxidation (15). PGC-1 has also been
shown to be upregulated in response to exercise train-
ing (13,16,17), making it an attractive candidate for ex-
plaining improvements in FAO with physical activity in
obese individuals (13) or as a target for the development of
antiobesity or antidiabetic drugs. The objectives of the
present study were as follows: 1) to determine whether
obesity-related impairments in FAO were associated with
a reduction in myocyte mitochondrial content and 2)t o
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the myocytes of obese individuals could normalize abso-
lute rates of FAO in a manner similar to that associated
with exercise training (13). We have previously reported
that primary human skeletal muscle cell cultures (HSkMC)
display the phenotype of skeletal muscle from obese
individuals with respect to a reduction in FAO (11); we
thus utilized this model to examine mechanisms control-
ling FAO and to speciﬁcally manipulate PGC-1.
RESEARCH DESIGN AND METHODS
Muscle biopsies (50–100 mg) were obtained from the vastus lateralis of lean
(BMI 22.4  0.9 kg/m
2; N  12) and extremely obese (BMI 45.3  1.4 kg/m
2;
N  9) women with the percutaneous needle biopsy technique. Satellite cells
were isolated and cultured into myoblasts as previously described (18,19).
After reaching 70% conﬂuency, cells were subcultured to examine the
recombinant adenoviral overexpression of PGC-1 on FAO, markers of
mitochondrial content, and lipid accumulation as described below. All proce-
dures were approved by the East Carolina University Institutional Review
Board.
Recombinant adenovirus. Recombinant adenoviruses encoding mouse
PGC-1 (Ad-PGC-1)o r-galactosidase (Ad--gal) were constructed, ampli-
ﬁed, and puriﬁed as described previously (17). Ad--gal was used to control
for nonspeciﬁc effects of virus treatment.
Overexpression of PGC-1 in HSkMC. Myoblasts were subcultured onto 6-
and 24-well type I collagen-coated plates at densities of 80 and 20 	 10
3 cells
per well, respectively. Upon reaching 70–80% conﬂuence, differentiation to
myotubes was induced by switching the growth media to differentiation media
(Dulbecco’s Modiﬁed Eeagle’s Medium supplemented with 2% horse serum,
0.5 mg/ml BSA, 0.5 mg/ml fetuin, and 50 
g/ml gentamicin/amphotericin B). On
day ﬁve, myotubes were given fresh differentiation media (no-virus control) or
transfected with either Ad-PGC-1 or Ad--gal (control virus). To determine
the appropriate adenoviral titer to use for metabolic experiments, we initially
performed a protein (Fig. 1) and mRNA (not shown) dose-response curve.
For all subsequent experiments, a “low” Ad-PGC-1 dose (5 	 10
9
plaque-forming units/ml) was used to mimic the effects of endurance exercise
(3.5-fold increase in PGC-1 protein over controls) (20) and a “high”
Ad-PGC-1 dose (1 	 10
10 plaque-forming units/ml) used to represent a
supraphysiological increase in PGC-1 (approximately eightfold increase in
PGC-1 protein over control). Twenty-four hours after transfection, the
medium was removed and replaced with fresh differentiation media. Myo-
tubes were harvested for respective experiments on day eight based on
previous research (19). There were no obvious differences in the extent of
myotube differentiation between lean and obese HSkMC.
Determination of FAO and lipid esteriﬁcation. On day eight of differen-
tiation, myotubes were incubated at 37°C in sealed 24-well plates containing
differentiation media, 12.5 mmol/l HEPES, 0.5% BSA, 1 mmol/l carnitine, either
100 
mol/l or 500 
mol/l sodium oleate (Sigma-Aldrich, St. Louis, MO), and
1 
Ci/ml [
14C] oleate (PerkinElmer, MA) for 3 h. Following incubation,
medium was assayed for
14CO2 (measure of complete oxidation), and radio-
labeled acid soluble metabolites (ASM) (measure of incomplete oxidation) as
previously described (19). Cells were washed twice with PBS, harvested in 600

l of 0.05% SDS lysis buffer, and stored at 80°C for subsequent determination
of protein concentration and lipid esterﬁcation.
For determination of lipid esterﬁcation, 500 
l cell lysate was added to 1:2
chloroform:methanol (vol/vol). After vortexing, 625 
l chloroform was added,
followed by the addition of 625 
l deionized H2O. Samples were vortexed and
centrifuged at 1,000 RPM for 5 min at room temperature. The chloroform
phase (containing total lipids extracted) was transferred to a clean glass tube
and evaporated under a stream of 100% N2. Samples were resuspended in 500

l of 2:1 chloroform:methanol. For the quantiﬁcation of total lipids, 50 
lo f
the sample was added to scintillation ﬂuid for counting. For determination of
speciﬁc lipid fractions, 50 
l of each sample was spotted onto oven-dried silica
plates (Silica Gel GF; Analtech, Newark, DE), and placed in a sealed tank
containing solvent (60:40:3 heptane:isopropyl ether:acetic acid) for 45 min.
Plates were air-dried and scanned for the visualization of the bands repre-
senting triacylglycerol (TAG), diacylglycerol (DAG), and phospholipid (PL).
DNA isolation and mtDNA quantiﬁcation. Cells were washed twice with
PBS and trypsinized with trypsin-EDTA (0.05% trypsin and 0.02% EDTA). Total
DNA (mitochondrial and nuclear) was extracted from cells using a QIAamp
DNA minikit (Qiagen, Valencia, CA) and total DNA quantiﬁed using the
PicoGreen DNA quantiﬁcation kit (Molecular Probes, Eugene,OR). mtDNA
content was measured as relative copy number of mtDNA per diploid nuclear
genome using real-time PCR. As recommended by Miller et al. (21), detection
of a 69-bp fragment of mtDNA (nucleotides 14918–14986) and a 77-bp
fragment of -globin were used as markers of mtDNA and nuclear DNA,
respectively. Primer and probe sets were purchased from Applied Biosystems
(Foster City, CA) using sequences previously reported by Menshikova et al.
(22). Real-time PCR was conducted using an ABI Prism 7900HT sequence
detection system under conditions previously described (22). The threshold
cycle number (Ct) was calculated using SDS software (version 2; Applied
Biosystems). mtDNA was expressed as a relative copy number (Rc) by
expressing Ct differences between -globin and mtDNA as previously de-
scribed (23,24) and based on the following calculations: Rc  2
Ct and Ct 
Ct-globin  CtmtDNA.
Western blot Analyses. Cells were washed twice with ice-cold PBS and
harvested in 150 
l lysis buffer (50 mmol/l HEPES [pH 7.4], 1% Triton X-100,
10 mmol/l EDTA, 100 mmol/l NaFl, and 12 mmol/l Na pyrophosphate)
supplemented with protease and phosphatate inhibitors (Sigma-Aldrich).
Samples were sonicated and centrifuged at 20,000g for 20 min at 4°C. Protein
concentrations were determined from cell extracts using the bicinchoninic
acid assay (Pierce Biotechnology, Rockford, IL). Thirty micrograms of cellular
protein were separated by SDS-PAGE and electrotransferred onto polyvinyli-
dene diﬂuoride membranes (Millipore, Billerica, MA) and probed overnight for
either PGC-1 (1:500; Cell Signaling, Beverly, MA), mitochondrial transcrip-
tion factor (mtTFA) (1:500; Santa Cruz Biotechnologies, Santa Cruz, CA), or
cytochrome C oxidase (COX)IV (1:8,000; Cell Signaling). Samples were
normalized to a control sample on each gel.
Statistics. Comparisons between HSkMC from lean and obese donors were
performed with repeated-measures ANOVA. Signiﬁcant main effects and
interactions were further analyzed using contrast-contrast tests when appro-
priate. Statistical signiﬁcance was deﬁned as a P value 0.05, and data are
presented as means  SE.
RESULTS
PGC-1 overexpression. Findings from the dose-re-
sponse experiment for Ad-PGC-1 are presented in Fig. 1.
Treatment of myotubes with Ad--gal (control virus) had
no effect on PGC-1 protein content compared with that
on no-virus controls (Fig. 1A). In HSkMC derived from
lean and obese individuals, PGC-1 protein (Fig. 1A) and
mRNA (data not shown) increased in a dose-dependent
manner with increasing PGC-1 adenovirus titer; there
were no differences between PGC-1 protein content in
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FIG. 1. Ad-PGC-1 overexpression in cultured myotubes (HSkMC)
from lean and obese donors. A: PGC-1 protein content in no-virus
controls (NVC), Ad--gal controls, and Ad-PGC-1–treated HSkMC.
PGC-1 protein content increased dose dependently in HSkMC from
lean and obese donors. B: mtTFA and COXIV protein content increased
dose dependently with increasing PGC-1 viral titer in HSkMC.
OBESITY, LIPID METABOLISM, AND PGC-1
1408 DIABETES, VOL. 59, JUNE 2010 diabetes.diabetesjournals.orgHSkMC from lean and obese individuals with or without
overexpression. Based on the ﬁndings presented in Fig.
1A, for subsequent experiments we selected the 1-ul dose
(5 	 10
9 plaque-forming units/ml) as PGC-1 protein
content was increased by a magnitude similar to that
reported with endurance-oriented exercise training (3.5-
fold increase in PGC-1 protein over control) (20) and the
2-
l dose (1 	 10
10 plaque-forming units/ml) to represent
a supraphysiological increment (approximately eightfold
increase in PGC-1 protein over controls) in protein
content. These doses are referred to as low and high
Ad-PGC-1, respectively. Protein levels of mtTFA and
COXIV, indicators of mitochondrial biogenesis, also in-
creased in a dose-dependent manner with PGC-1 adeno-
virus (Fig. 1B).
FAO. To evaluate the role of PGC-1 in regulating skeletal
muscle lipid oxidation, we treated myotubes from lean and
obese donors with either low or high Ad-PGC-1 for 24 h,
followed by 3 h incubation with either 100 or 500 
mol/l
oleate. In all experiments, FAO from the no-virus controls
did not differ from that in the Ad--gal controls (data not
shown). Data obtained from the experiments determining
FAO are presented in Fig. 2. Under control conditions (low
and high -gal), complete FAO (
14CO2 production) was
consistently depressed by 30% in HSkMC from obese
individuals with either the 100 or 500 
mol/l oleate incu-
bation (Fig. 2A and B). As presented in Fig. 2A, overex-
pression of PGC-1 by 3.5-fold (low dose) resulted in an
30% increase in complete FAO (100 
mol/l oleate) in
HSkMC derived from lean and obese donors. The eightfold
increase in PGC-1 protein (high dose) also increased
complete FAO in cells from both lean (64%) and obese
(70%) donors at the 100 
mol/l oleate concentration (P 
0.05) (Fig. 2A). Although PGC-1 overexpression in-
creased FAO regardless of the category of the donor,
absolute values for complete FAO remained depressed in
HSkMC derived from obese compared with those in lean
subjects under all conditions (Fig. 2A). Similar ﬁndings
were obtained in response to the higher oleate concentra-
tion (500 
mol/l) with respect to differences between cell
types and the effects of PGC-1 overexpression (Fig.
2B). Total FAO, determined as the sum of incomplete
([
14C]ASM) and complete ([
14CO2]) oxidation did not differ
between cell type under any conditions (Fig. 2C and D),
and PGC-1 overexpression increased total oxidation in a
dose-dependent manner. Total and complete FAO were
signiﬁcantly higher at 500 
mol/l oleate compared with
100 
mol/l oleate in control and PGC-1–treated cells (P 
0.05) (Fig. 2A–D).
A ratio of incomplete ([
14C]ASM) to complete (
14CO2)
oleate oxidation was calculated as an index of FAO
efﬁciency (14). In control cells treated with 100 
mol/l
[
14C]oleate, radiolabel incorporation into ASM relative to
CO2 was approximately twofold higher in myotubes from
obese compared with lean individuals (P  0.05) (Fig. 2E).
The high relative rate of incomplete oxidation in the obese
compared with the lean group was retained regardless of
the level of PGC-1 overexpression or oleate concentra-
tion (Fig. 2E and F). In cells from lean individuals, PGC-1
overexpression increased the ASM-to-CO2 ratio by 55%
(P  0.05); PGC-1 overexpression in cells from obese
subjects had no effect on this ratio (Fig. 2E and F). The
ASM/CO2 ratio was signiﬁcantly higher at 500 
mol/l
oleate compared with 100 
mol/l oleate in control and
PGC-1–treated cells (P  0.05) (Fig. 2E and F).
Intramyocellular lipid content. Oleate incorporation
into glycerolipid, TAG, and DAG pools are presented in
Fig. 3. Control cells (-gal) from obese individuals had a
greater rate of oleate incorporation into the glycerolipid
pool in response to low (64%) and high (42%) oleate
concentrations (Fig. 3A and B). Cells from obese individ-
uals, regardless of treatment, consistently incorporated
more lipids into the glycerolipid pool compared with
HSkMC from lean subjects (Fig. 3A and B). PGC-1
overexpression increased esteriﬁcation into the glycero-
lipid pool at both concentrations of oleate in both groups
of subjects.
Incorporation of lipid into TAG and DAG are presented
in Fig. 3C–F. Under control conditions, cells from obese
subjects had increased oleate incorporation into TAG (P 
0.05) (Fig. 3C and D) when exposed to low and high oleate
conditions. Lipid incorporation into DAG was higher (P 
0.05) (Fig. 3E) in obese cells compared with lean cells
when exposed to low oleate conditions. Oleate incorpora-
tion into PL did not differ between lean and obese control
cells regardless of oleate concentration (data not shown;
P  0.05). Compared with the control condition (-gal),
PGC-1 overexpression increased oleate incorporation
into TAG (P  0.05) (Fig. 3C and D) and PL (data not
shown; P  0.05) without affecting DAG. This was evident
in HSkMC from both lean and obese subjects (Fig. 3C–F).
PGC-1 overexpression did not normalize intramyocellu-
lar lipid incorporation into storage in HSkMC from obese
subjects to that of the lean individuals under the same
treatment (Fig. 3C and E). The rate of oleate incorporation
into glycerolipids (speciﬁcally, TAG and DAG) was higher
when cells were exposed to the higher oleate concentra-
tion (P  0.05) (Fig. 3A–F).
Lipid partitioning. Lipid partitioning was estimated by
determining the rate of lipid esteriﬁcation relative to
complete FAO; a higher ratio is indicative of increased
partitioning toward storage. Myotubes from obese do-
nors had a higher partitioning index compared with
HSkMC from lean donors (P  0.05) (Fig. 4A and B)
regardless of the oleate concentration. Overexpression
of PGC-1 at the low dose did not alter this ratio from
the control condition, whereas high-dose PGC-1 over-
expression (approximately eightfold increase in PGC-1
protein) decreased this ratio under low oleate condi-
tions (P  0.05) (Fig. 4A).
Indexes of mitochondrial content. mtDNA, COXIV, and
mtTFA protein content data are presented in Fig. 5.
mtDNA, COXIV, and mtTFA protein content were de-
pressed (27, 35, and 43%, respectively; P  0.05) (Fig.
5A–C) in control myotubes from obese compared with
lean donors. The overexpression of PGC-1 protein by
3.5-fold (low dose) increased mtDNA content by 27% in
HSkMC from lean and obese subjects, whereas increasing
PGC-1 protein approximately eightfold increased mtDNA
content by 66 and 72% in myotubes from lean and obese
individuals, respectively (P  0.05) (Fig. 5A). Overexpres-
sion of PGC-1 increased COXIV and mtTFA protein
content in a dose-dependent manner (P  0.05) (Fig.
5B and C). However, despite PGC-1 overexpression,
mtDNA, COXIV, and mtTFA protein content still remained
depressed in the cells from obese compared with lean
donors under the same experimental treatment (P  0.05)
(Fig. 5A–C).
FAO and mitochondrial content. As presented in Fig.
6, when complete FAO (
14CO2 production) at either 100
or 500 
mol/l oleate was expressed relative to mtDNA
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content, the decrement in FAO evident with obesity
(Fig. 2) was abolished. PGC-1 overexpression had no
effect on FAO relative to mtDNA (P  0.05) and
decreased FAO relative to COXIV protein content by
50% (P  0.05) (Fig. 6).
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FIG. 2. Effect of PGC-1 overexpression on FAO and oxidation efﬁciency in HSkMC from lean (f) and obese () donors. HSkMC cultured from
lean (n  12) and obese (n  9) donors was treated with either low- or high-dose recombinant Ad--gal or PGC-1 and incubated with either 100
mol/l (A, C, and E) or 500 (B, D, and F) mol/l [
14C] oleate. Complete FAO was measured from
14C-labeled incorporation into CO2 (A and B).
Total FAO (C and D) was measured as the sum of
14C-labeled incorporation into CO2 and
14C-labeled incorporation into ASMs, with ASM serving
as an index of incomplete FAO. Oxidation efﬁciency was determined as the ratio of ASM to complete FAO, represented as ASM/CO2 (E and F),
with higher values indicative of reduced efﬁciency. Data are expressed as means  SE and signiﬁcant differences denoted at the P < 0.05 level.
*Signiﬁcant difference between lean and obese for that treatment. †Signiﬁcant main effect comparing control (-gal) and PGC-1  overexpression
(Ad-PGC-1) at the respective adenoviral doses. ‡Signiﬁcant difference between the high and low Ad-PGC-1 doses. §Signiﬁcant increase in lean
subjects with PGC-1 overexpression compared with control at the respective adenoviral doses.
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The intent of the current study was to determine whether
the low rates of skeletal muscle FAO observed in obese
humans could be linked to a lower mitochondrial content
in skeletal muscle and, given the role of PGC-1 in
stimulating mitochondrial biogenesis, to examine whether
increasing PGC-1 by a physiologically relevant increment
could mitigate the foregoing deﬁcits. HSkMC was selected
as the experimental model because myotubes established
in culture from extremely obese donors display a reduc-
tion in FAO that is quantitatively similar to that reported in
skeletal muscle strips (60%) (3), muscle homogenates
(50%) (2), and in vivo studies using
13C tracers (22%) (5) or
indirect calorimetry (40%) (4). Other reports have likewise
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tion assessed in vivo in healthy young men was preserved
in HSkMC (25). Our present ﬁndings (Fig. 2) further
establish the utility of HSkMC as a model for studying fuel
metabolism in human skeletal muscle.
There is controversy whether the reduction in complete
FAO in human skeletal muscle observed with obesity can
be attributed to the existing mitochondria being dysfunc-
tional (i.e., altered morphology), the existing mitochondria
being fully functional but expressed at a lower concentra-
tion with obesity, or a combination of both of these
conditions (26). An important ﬁnding of the present study
was that although complete FAO and mitochondrial con-
tent were reduced in HSkMC from extremely obese donors
(Figs. 2 and 5), when complete FAO was normalized to
indexes of mitochondrial content, the differences between
lean and obese subjects were abolished (Fig. 6). The
ﬁnding that the reduced complete FAO in myocytes from
obese donors is associated with reduced mitochondrial
content (Fig. 6) suggests that the impairment in complete
FAO in human skeletal muscle with obesity may be
attributed, at least in part, to a reduction in mitochondrial
content (Fig. 5). This obesity phenotype is akin to charac-
teristics exhibited by type 2 muscle ﬁbers; in support, a
greater proportion of type 2 ﬁbers has been reported with
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traits of glycolytic tissue (i.e., contractile properties) are
retained in cell culture. While our data suggest that
mitochondrial functionality remains intact with obesity,
more extensive mitochondrial characterization (i.e., respi-
ration data) is needed to provide deﬁnitive conclusions.
In support of our ﬁndings, Holloway et al. (6) have
reported that FAO in mitochondria isolated from muscle
biopsies was reduced with obesity when calculated on a
whole-muscle basis; however, when normalized to mito-
chondrial protein content, FAO was equivalent in lean and
obese. The present ﬁndings add to the existing data (6) in
two novel ways. First, the absolute decrement in complete
FAO (Fig. 2) and associated reduction in mitochondrial
content (Figs. 5 and 6) with obesity were evident even
when mitochondrial content was manipulated via PGC-1
overexpression, indicating consistency. Second, to our
knowledge this is the ﬁrst study to demonstrate a reduc-
tion in mitochondrial content in primary human muscle
cell cultures from obese donors. It has been proposed that
characteristics evident in HSkMC have a genetic origin,
given that any phenotype is retained as the cells proliferate
and differentiate independently of in vivo inﬂuences
(11,25,28). The current data thus provide the novel infor-
mation that the reduction in mitochondrial content and the
accompanying decrement in FAO in skeletal muscle from
extremely obese subjects consist of a heritable or im-
printed component.
PGC-1 is considered a “master regulator” coordinating
mitochondrial biogenesis because elevating PGC-1 con-
tent activates critical downstream transcription factors,
which effectively remodel the muscle cell to favor oxida-
tive metabolism (17,29–32). Accordingly, in L6 muscle
cells the overexpression of PGC-1 enhanced FAO and
increased the expression of genes involved in oxidative
processes (17); an elevation in PGC-1 is also believed to
be a critical factor accounting for the increased FAO and
mitochondrial content in skeletal muscle with exercise
training (16,17). In the present study, while PGC-1 over-
expression increased FAO and mitochondrial content in-
dependently of body composition, absolute values for
complete FAO and mitochondrial content remained de-
pressed in the myocytes from obese subjects at both the
physiological and supraphysiological PGC-1 doses (Figs.
2 and 5). This novel result indicates that skeletal muscle of
obese individuals responds to signals triggered by PGC-1;
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drial biogenesis and oxidative capacity via mechanisms
that are independent of PGC-1 abundance (Figs. 2 and 5).
The differences between the lean and obese myocytes in
indexes of mitochondrial content (Fig. 5) and FAO (Fig. 2)
were relatively consistent with and without (control)
PGC-1 overexpression; this suggests a possible reduction
in another coactivator or mechanism involved with mito-
chondrial proliferation. mtTFA protein content, a tran-
scription factor downstream of PGC-1 critical for mtDNA
replication (33), mirrored the pattern of change seen in
mitochondrial content (Fig. 5), suggesting that the defect
with obesity may involve this arm of PGC-1 coordination.
A combination of variables such as PGC-1 cellular loca-
tion (cytoplasm vs. nucleus), posttranslational modiﬁca-
tions (i.e., acetylation and phosphorylation), and PGC-1
binding to or activation of transcription factors could
contribute to the mitochondrial phenotype of obese
HSkMC. Given the complexity of mitochondrial biogenesis,
mechanisms independent of PGC-1 could also explain the
obesity-associated decrement in FAO and mitochondrial
content (34). Although the precise mechanism(s) are yet
unknown, the present data indicate that extreme human
obesity involves an intrinsic impairment in skeletal muscle
mitochondrial biogenesis and content.
We previously reported that exercise training increased
complete FAO and improved oxidation efﬁciency (CO2
production/ASM) to equivalent absolute values in lean and
formerly extremely obese individuals despite an initial
decrement in FAO and elevated ASM production in the
obese subjects (13). As presented in Fig. 2, increasing
PGC-1 content by both physiological and supraphysi-
ological increments did not abolish the difference in
complete FAO and oxidation efﬁciency between lean and
obese subjects as opposed to the total normalization seen
with exercise training (13). This ﬁnding further suggests
that other exercise factors, in addition to an increase in
PGC-1 content, account for the improvement in skeletal
muscle FAO with physical activity in obese individuals
(13).
Despite the reduced ability to completely oxidize lipid,
obese cells exhibited similar rates of total oxidation,
suggesting a downstream defect in the lipid oxidation
pathway. Koves et al. (17) suggested that an elevated
ASM/CO2 ratio, as observed in cells derived from obese
donors (Fig. 2), signiﬁes a mismatch between -oxidation
relative to trichloroacetic acid cycle activity. It is plausible
that this occurred in the present study and that products
of oxidative metabolism accumulated when downstream
metabolic pathways could not adjust appropriately. In
addition, obesity was linked to preferential partitioning of
FA into the glycerolipid (TAG and DAG) pools (Fig. 3).
These abnormalities are clinically relevant because both
incomplete FAO and intramuscular lipid accumulation
have been implicated as markers and perhaps mediators of
insulin resistance in obese individuals (35,36).
Interestingly, PGC-1 overexpression increased fatty
acid incorporation into TAG but not DAG (Fig. 3). This
ﬁnding is consistent with a recent report showing that
transgenic mice with muscle-speciﬁc overexpression of
PGC-1 have increased muscle TAG when fed a high-fat
diet (37). In this mouse model, PGC-1 overexpression
resulted in upregulation of diacylglycerol aclytransferase
and mitochondrial glycerol-3-PO4 acyl-transferase, two
enzymes involved in TAG synthesis; we speculate that
similar mechanisms might be operative in the HSkMC.
PGC-1 overexpression had little effect on overall lipid
partitioning (Fig. 4) because improved rates of FAO (Fig.
2) were matched by accelerated rates of glycerolipid and
TAG synthesis (Fig. 3). Increasing the expression of
PGC-1 thus did not rescue the cells from the obese
subjects in terms of returning the indexes of lipid storage
(Figs. 3 and 4) to values seen in the cells from lean donors.
In summary, skeletal muscle cells cultured from ex-
tremely obese donors exhibited depressed mitochondrial
content, which could in turn be responsible for the dimin-
ished capacity to oxidize lipid and the preferential parti-
tioning of lipid toward intramuscular storage with obesity.
This phenotype may consist of a heritable or imprinted
component because it is proposed that characteristics
expressed in HSkMC have a genetic origin. When PGC-1
was overexpressed in HSkMC from lean and obese sub-
jects, the mitochondrial phenotype of obesity persisted.
This ﬁnding suggests a molecular impairment in mitochon-
drial proliferation that occurs independent or downstream
of PGC-1 expression. Additionally, PGC-1 overexpres-
sion did not fully recapitulate the effects of exercise
training on FAO in obese individuals, suggesting that
additional mechanisms are involved with this intervention.
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